Marilyn Grace Liang, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vascular Malformations | 17 | 2024 | 464 | 3.830 |
Why?
|
Neurocutaneous Syndromes | 6 | 2024 | 53 | 2.420 |
Why?
|
Hemangioma | 15 | 2024 | 727 | 2.240 |
Why?
|
Capillaries | 11 | 2023 | 744 | 2.030 |
Why?
|
Aortic Coarctation | 5 | 2024 | 282 | 1.960 |
Why?
|
Eye Abnormalities | 6 | 2024 | 241 | 1.950 |
Why?
|
Abnormalities, Multiple | 6 | 2023 | 1414 | 1.210 |
Why?
|
Erythema | 2 | 2020 | 262 | 1.180 |
Why?
|
Lymphatic Abnormalities | 2 | 2023 | 132 | 1.120 |
Why?
|
Pleural Effusion | 2 | 2023 | 342 | 1.090 |
Why?
|
Myofibromatosis | 1 | 2023 | 27 | 0.860 |
Why?
|
Skin Diseases | 6 | 2024 | 1088 | 0.840 |
Why?
|
Skin | 6 | 2024 | 4464 | 0.820 |
Why?
|
Pemphigus | 1 | 2022 | 116 | 0.760 |
Why?
|
Mucositis | 1 | 2022 | 108 | 0.760 |
Why?
|
Paraneoplastic Syndromes | 1 | 2022 | 155 | 0.740 |
Why?
|
Bronchiolitis Obliterans | 1 | 2022 | 213 | 0.740 |
Why?
|
Facial Hemiatrophy | 1 | 2020 | 24 | 0.730 |
Why?
|
Infant | 46 | 2024 | 36054 | 0.720 |
Why?
|
Arteriovenous Malformations | 1 | 2023 | 397 | 0.710 |
Why?
|
Veins | 4 | 2021 | 765 | 0.710 |
Why?
|
Arteriovenous Fistula | 1 | 2023 | 313 | 0.710 |
Why?
|
Skin Neoplasms | 15 | 2024 | 5797 | 0.690 |
Why?
|
Pyoderma Gangrenosum | 1 | 2020 | 84 | 0.640 |
Why?
|
Craniosynostoses | 1 | 2023 | 412 | 0.640 |
Why?
|
Progeria | 3 | 2016 | 188 | 0.600 |
Why?
|
Wilms Tumor | 2 | 2017 | 375 | 0.590 |
Why?
|
Mucous Membrane | 1 | 2021 | 656 | 0.580 |
Why?
|
Telangiectasis | 1 | 2017 | 77 | 0.570 |
Why?
|
Genitalia | 1 | 2017 | 113 | 0.570 |
Why?
|
Skin Diseases, Vascular | 1 | 2017 | 41 | 0.570 |
Why?
|
Dermatitis, Toxicodendron | 1 | 2016 | 4 | 0.550 |
Why?
|
Umbilical Cord | 1 | 2017 | 181 | 0.530 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2019 | 329 | 0.530 |
Why?
|
Child, Preschool | 31 | 2024 | 42058 | 0.490 |
Why?
|
Ichthyosis Vulgaris | 1 | 2014 | 2 | 0.470 |
Why?
|
Earache | 1 | 2014 | 14 | 0.470 |
Why?
|
Ichthyosis, Lamellar | 1 | 2014 | 11 | 0.470 |
Why?
|
Infant, Newborn | 27 | 2024 | 26182 | 0.460 |
Why?
|
Child | 41 | 2024 | 79813 | 0.460 |
Why?
|
Skin Ulcer | 4 | 2011 | 129 | 0.450 |
Why?
|
Hypopituitarism | 2 | 2014 | 250 | 0.450 |
Why?
|
Headache | 2 | 2024 | 1248 | 0.450 |
Why?
|
Sirolimus | 1 | 2021 | 1533 | 0.450 |
Why?
|
Dermatology | 1 | 2023 | 914 | 0.420 |
Why?
|
Fibrosarcoma | 2 | 2012 | 308 | 0.420 |
Why?
|
Vascular Diseases | 1 | 2021 | 1160 | 0.410 |
Why?
|
Tetralogy of Fallot | 1 | 2017 | 631 | 0.400 |
Why?
|
Nevus, Pigmented | 1 | 2014 | 221 | 0.390 |
Why?
|
Sweet Syndrome | 1 | 2011 | 58 | 0.380 |
Why?
|
Leukemia | 1 | 2019 | 1519 | 0.370 |
Why?
|
Subcutaneous Tissue | 2 | 2021 | 132 | 0.360 |
Why?
|
Autoimmune Diseases | 1 | 2022 | 2244 | 0.350 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2014 | 546 | 0.340 |
Why?
|
Deafness | 1 | 2014 | 457 | 0.340 |
Why?
|
Inflammatory Bowel Diseases | 2 | 2023 | 2420 | 0.330 |
Why?
|
Hand | 2 | 2012 | 903 | 0.330 |
Why?
|
Diagnosis, Differential | 13 | 2023 | 12951 | 0.320 |
Why?
|
Human Growth Hormone | 1 | 2014 | 638 | 0.320 |
Why?
|
Ultraviolet Rays | 1 | 2014 | 1076 | 0.320 |
Why?
|
Infant, Newborn, Diseases | 1 | 2014 | 592 | 0.320 |
Why?
|
Connective Tissue | 1 | 2010 | 416 | 0.310 |
Why?
|
Chickenpox Vaccine | 2 | 2018 | 40 | 0.310 |
Why?
|
Immunosuppressive Agents | 1 | 2021 | 4158 | 0.300 |
Why?
|
Glucose Transporter Type 1 | 1 | 2008 | 186 | 0.290 |
Why?
|
Hearing Loss | 1 | 2014 | 780 | 0.270 |
Why?
|
Terminology as Topic | 2 | 2013 | 1533 | 0.270 |
Why?
|
Musculoskeletal Abnormalities | 2 | 2017 | 100 | 0.270 |
Why?
|
Adolescent | 26 | 2024 | 87888 | 0.270 |
Why?
|
Sjogren-Larsson Syndrome | 1 | 2005 | 2 | 0.270 |
Why?
|
Keratoderma, Palmoplantar | 1 | 2005 | 17 | 0.260 |
Why?
|
Humans | 78 | 2024 | 758381 | 0.260 |
Why?
|
Nevus | 2 | 2017 | 205 | 0.250 |
Why?
|
Soft Tissue Neoplasms | 2 | 2024 | 1152 | 0.250 |
Why?
|
Herpes Zoster | 2 | 2018 | 251 | 0.250 |
Why?
|
Exanthema | 2 | 2023 | 504 | 0.250 |
Why?
|
Lipoma | 2 | 2017 | 292 | 0.250 |
Why?
|
Blood Vessels | 1 | 2010 | 1112 | 0.240 |
Why?
|
Female | 52 | 2024 | 390316 | 0.230 |
Why?
|
Severity of Illness Index | 7 | 2024 | 15785 | 0.230 |
Why?
|
Retrospective Studies | 22 | 2023 | 80170 | 0.230 |
Why?
|
Laryngeal Neoplasms | 1 | 2008 | 514 | 0.230 |
Why?
|
Nevus, Blue | 1 | 2024 | 43 | 0.230 |
Why?
|
p120 GTPase Activating Protein | 1 | 2023 | 36 | 0.230 |
Why?
|
Kidney Neoplasms | 2 | 2017 | 4312 | 0.220 |
Why?
|
Hemangioma, Capillary | 2 | 2015 | 62 | 0.220 |
Why?
|
Male | 46 | 2024 | 358742 | 0.220 |
Why?
|
Hemangioendothelioma | 3 | 2012 | 111 | 0.220 |
Why?
|
Facial Neoplasms | 3 | 2016 | 125 | 0.220 |
Why?
|
Hypersensitivity, Delayed | 1 | 2024 | 490 | 0.220 |
Why?
|
Hydrops Fetalis | 1 | 2023 | 109 | 0.210 |
Why?
|
Cranial Sutures | 1 | 2023 | 92 | 0.210 |
Why?
|
Gastrointestinal Neoplasms | 2 | 2024 | 951 | 0.210 |
Why?
|
Face | 2 | 2020 | 1017 | 0.210 |
Why?
|
Lipomatosis | 1 | 2023 | 112 | 0.200 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2023 | 184 | 0.200 |
Why?
|
Young Adult | 12 | 2024 | 58808 | 0.200 |
Why?
|
Neonatal Screening | 2 | 2017 | 594 | 0.200 |
Why?
|
Neoplasms, Connective Tissue | 1 | 2021 | 36 | 0.200 |
Why?
|
Ascites | 1 | 2023 | 338 | 0.190 |
Why?
|
Age Distribution | 3 | 2017 | 2882 | 0.190 |
Why?
|
Klippel-Trenaunay-Weber Syndrome | 2 | 2013 | 69 | 0.190 |
Why?
|
Carcinoma | 1 | 2012 | 2330 | 0.180 |
Why?
|
Granuloma, Pyogenic | 1 | 2020 | 47 | 0.180 |
Why?
|
Herpesvirus 3, Human | 2 | 2018 | 158 | 0.170 |
Why?
|
Tuberculosis, Cutaneous | 1 | 1999 | 17 | 0.170 |
Why?
|
Perineum | 2 | 2002 | 208 | 0.170 |
Why?
|
Facial Muscles | 1 | 2020 | 159 | 0.170 |
Why?
|
Hematologic Neoplasms | 1 | 2011 | 1890 | 0.170 |
Why?
|
Papilloma | 1 | 2020 | 141 | 0.170 |
Why?
|
Germ Cells | 1 | 2023 | 635 | 0.160 |
Why?
|
Skin Diseases, Viral | 1 | 1998 | 26 | 0.150 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 895 | 0.150 |
Why?
|
Rhabdoid Tumor | 1 | 2020 | 210 | 0.150 |
Why?
|
Eye Diseases | 1 | 2023 | 651 | 0.150 |
Why?
|
Social Stigma | 1 | 2024 | 763 | 0.150 |
Why?
|
Umbilicus | 1 | 2017 | 38 | 0.150 |
Why?
|
Lip Diseases | 1 | 1997 | 18 | 0.140 |
Why?
|
Arthritis | 1 | 2002 | 666 | 0.140 |
Why?
|
Developmental Disabilities | 1 | 2005 | 1504 | 0.140 |
Why?
|
Delayed Diagnosis | 1 | 2020 | 463 | 0.140 |
Why?
|
GTP-Binding Protein alpha Subunits | 1 | 2017 | 102 | 0.130 |
Why?
|
Angiofibroma | 1 | 2016 | 55 | 0.130 |
Why?
|
Piperidines | 2 | 2016 | 1639 | 0.130 |
Why?
|
Parotid Neoplasms | 1 | 2017 | 157 | 0.130 |
Why?
|
Rheumatic Diseases | 1 | 2002 | 639 | 0.130 |
Why?
|
Early Diagnosis | 1 | 2020 | 1177 | 0.130 |
Why?
|
Congenital Abnormalities | 2 | 2010 | 704 | 0.130 |
Why?
|
Rare Diseases | 2 | 2017 | 619 | 0.120 |
Why?
|
Melanoma | 1 | 2014 | 5691 | 0.120 |
Why?
|
Immunohistochemistry | 3 | 2024 | 11070 | 0.120 |
Why?
|
Phospholipase C gamma | 1 | 2015 | 130 | 0.120 |
Why?
|
Sex Distribution | 2 | 2017 | 2283 | 0.120 |
Why?
|
Psoriasis | 1 | 2023 | 938 | 0.120 |
Why?
|
Fatal Outcome | 1 | 2019 | 1829 | 0.120 |
Why?
|
Empty Sella Syndrome | 1 | 2014 | 14 | 0.120 |
Why?
|
Pravastatin | 1 | 2016 | 392 | 0.120 |
Why?
|
Syndrome | 4 | 2011 | 3262 | 0.110 |
Why?
|
Urticaria | 1 | 2015 | 150 | 0.110 |
Why?
|
Immunization | 1 | 1998 | 1227 | 0.110 |
Why?
|
Popliteal Vein | 1 | 2013 | 43 | 0.110 |
Why?
|
Glucocorticoids | 4 | 2016 | 2144 | 0.110 |
Why?
|
Adult | 16 | 2024 | 219916 | 0.110 |
Why?
|
Administration, Oral | 1 | 2021 | 3993 | 0.100 |
Why?
|
Farnesyltranstransferase | 1 | 2012 | 71 | 0.100 |
Why?
|
Pruritus | 1 | 2016 | 377 | 0.100 |
Why?
|
Lower Extremity | 1 | 2021 | 1188 | 0.100 |
Why?
|
Pyridines | 2 | 2016 | 2860 | 0.100 |
Why?
|
Fibroblasts | 1 | 2002 | 4087 | 0.100 |
Why?
|
Societies, Medical | 1 | 2024 | 3891 | 0.100 |
Why?
|
Hypertrophy | 1 | 2013 | 555 | 0.100 |
Why?
|
Cold Temperature | 1 | 2015 | 780 | 0.100 |
Why?
|
Diphosphonates | 1 | 2016 | 636 | 0.100 |
Why?
|
Extremities | 1 | 2017 | 865 | 0.090 |
Why?
|
Quality of Life | 3 | 2024 | 13286 | 0.090 |
Why?
|
Boston | 4 | 2022 | 9304 | 0.090 |
Why?
|
Saphenous Vein | 1 | 2013 | 517 | 0.090 |
Why?
|
Imidazoles | 1 | 2016 | 1179 | 0.090 |
Why?
|
Agammaglobulinemia | 1 | 2011 | 173 | 0.090 |
Why?
|
Upper Extremity | 1 | 2015 | 661 | 0.080 |
Why?
|
Mental Health | 1 | 2024 | 3232 | 0.080 |
Why?
|
Databases, Factual | 4 | 2017 | 7980 | 0.080 |
Why?
|
Endothelial Cells | 1 | 2022 | 3533 | 0.080 |
Why?
|
Sarcoma, Kaposi | 1 | 2012 | 374 | 0.080 |
Why?
|
Follow-Up Studies | 7 | 2017 | 39060 | 0.080 |
Why?
|
Vaccination | 2 | 2018 | 3356 | 0.080 |
Why?
|
Tuberous Sclerosis | 1 | 2016 | 1030 | 0.080 |
Why?
|
Risk Assessment | 6 | 2017 | 23883 | 0.080 |
Why?
|
Arm | 3 | 2017 | 583 | 0.070 |
Why?
|
Endothelium, Lymphatic | 2 | 2024 | 63 | 0.070 |
Why?
|
Gastrointestinal Diseases | 2 | 2006 | 1185 | 0.070 |
Why?
|
Epidermolysis Bullosa | 1 | 2007 | 29 | 0.070 |
Why?
|
Leukocytes | 1 | 2015 | 2025 | 0.070 |
Why?
|
Genomics | 1 | 2023 | 5789 | 0.070 |
Why?
|
Chilblains | 1 | 2006 | 16 | 0.070 |
Why?
|
Eponyms | 1 | 2006 | 14 | 0.070 |
Why?
|
Glottis | 1 | 2008 | 214 | 0.070 |
Why?
|
Incidence | 4 | 2017 | 21273 | 0.070 |
Why?
|
Lymphatic Vessels | 1 | 2010 | 358 | 0.070 |
Why?
|
Hospitals, Pediatric | 4 | 2016 | 1854 | 0.070 |
Why?
|
Neoplasms, Vascular Tissue | 1 | 2005 | 25 | 0.070 |
Why?
|
Cicatrix | 1 | 2011 | 781 | 0.060 |
Why?
|
Angiomatosis | 1 | 2005 | 46 | 0.060 |
Why?
|
Comorbidity | 2 | 2017 | 10495 | 0.060 |
Why?
|
Muscular Diseases | 1 | 2010 | 551 | 0.060 |
Why?
|
Cardiovascular Abnormalities | 1 | 2006 | 143 | 0.060 |
Why?
|
Laryngostenosis | 1 | 2007 | 167 | 0.060 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 2006 | 169 | 0.060 |
Why?
|
Age Factors | 2 | 2019 | 18357 | 0.060 |
Why?
|
Heart | 1 | 2017 | 4382 | 0.060 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2024 | 693 | 0.060 |
Why?
|
Caregivers | 1 | 2016 | 2224 | 0.060 |
Why?
|
Dermatitis, Atopic | 1 | 2011 | 716 | 0.060 |
Why?
|
Ultrasonography | 1 | 2017 | 5952 | 0.060 |
Why?
|
Leg | 3 | 2017 | 1087 | 0.060 |
Why?
|
Health Surveys | 1 | 2014 | 4060 | 0.060 |
Why?
|
Ectodermal Dysplasia | 1 | 2004 | 106 | 0.060 |
Why?
|
Mutation | 5 | 2020 | 29915 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 3 | 2020 | 36285 | 0.050 |
Why?
|
Lung | 1 | 2022 | 9985 | 0.050 |
Why?
|
Disease Progression | 2 | 2014 | 13468 | 0.050 |
Why?
|
Blister | 1 | 2003 | 86 | 0.050 |
Why?
|
Vascular Neoplasms | 1 | 2024 | 167 | 0.050 |
Why?
|
Stereotyping | 1 | 2024 | 240 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2012 | 3709 | 0.050 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2024 | 244 | 0.050 |
Why?
|
Middle Aged | 8 | 2024 | 219560 | 0.050 |
Why?
|
Cohort Studies | 4 | 2017 | 41252 | 0.050 |
Why?
|
Pemphigoid, Bullous | 1 | 2003 | 114 | 0.050 |
Why?
|
Drug Eruptions | 1 | 2024 | 335 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2015 | 15225 | 0.050 |
Why?
|
Prednisone | 2 | 2002 | 1565 | 0.050 |
Why?
|
Pilot Projects | 1 | 2014 | 8554 | 0.040 |
Why?
|
Thrombocytopenia | 2 | 2005 | 1172 | 0.040 |
Why?
|
Mass Screening | 1 | 2016 | 5425 | 0.040 |
Why?
|
Inflammation | 1 | 2020 | 10719 | 0.040 |
Why?
|
Carotid Arteries | 2 | 2016 | 939 | 0.040 |
Why?
|
Cross-Sectional Studies | 4 | 2024 | 25953 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2015 | 4313 | 0.040 |
Why?
|
Dermatomyositis | 1 | 2002 | 256 | 0.040 |
Why?
|
Immunocompromised Host | 1 | 2004 | 856 | 0.040 |
Why?
|
Registries | 1 | 2015 | 8176 | 0.040 |
Why?
|
Methotrexate | 2 | 2002 | 1719 | 0.040 |
Why?
|
Time Factors | 2 | 2017 | 39873 | 0.040 |
Why?
|
Canada | 1 | 2024 | 2111 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2016 | 5403 | 0.040 |
Why?
|
Celiac Disease | 1 | 2006 | 822 | 0.040 |
Why?
|
Cell Proliferation | 1 | 2014 | 10417 | 0.040 |
Why?
|
Hand Dermatoses | 1 | 1998 | 62 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 17768 | 0.040 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2024 | 1765 | 0.040 |
Why?
|
Prevalence | 1 | 2014 | 15646 | 0.030 |
Why?
|
Treatment Outcome | 6 | 2017 | 64379 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 2002 | 1630 | 0.030 |
Why?
|
Parotid Gland | 1 | 2017 | 175 | 0.030 |
Why?
|
Protein Prenylation | 1 | 2016 | 69 | 0.030 |
Why?
|
Shoulder | 1 | 1998 | 299 | 0.030 |
Why?
|
Melena | 1 | 2015 | 32 | 0.030 |
Why?
|
NF-kappa B | 1 | 2004 | 2472 | 0.030 |
Why?
|
Sickness Impact Profile | 1 | 2016 | 298 | 0.030 |
Why?
|
Hemangioma, Cavernous | 1 | 2015 | 107 | 0.030 |
Why?
|
Thorax | 1 | 1998 | 553 | 0.030 |
Why?
|
Mesentery | 1 | 2015 | 202 | 0.030 |
Why?
|
Pain | 1 | 2010 | 5065 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2017 | 8530 | 0.030 |
Why?
|
Homeodomain Proteins | 1 | 2024 | 2413 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2023 | 1585 | 0.030 |
Why?
|
Calcinosis | 1 | 2002 | 1467 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2024 | 2800 | 0.030 |
Why?
|
Practice Guidelines as Topic | 2 | 2024 | 7377 | 0.030 |
Why?
|
Leg Length Inequality | 1 | 2013 | 56 | 0.030 |
Why?
|
Anti-Inflammatory Agents | 1 | 2002 | 1793 | 0.030 |
Why?
|
Radiography | 2 | 2015 | 6955 | 0.030 |
Why?
|
Antirheumatic Agents | 1 | 2002 | 1368 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2016 | 12096 | 0.030 |
Why?
|
Risk Factors | 3 | 2014 | 73806 | 0.030 |
Why?
|
Evidence-Based Medicine | 1 | 2024 | 3671 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2023 | 4342 | 0.020 |
Why?
|
Immunoenzyme Techniques | 2 | 2005 | 1705 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2023 | 3615 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2024 | 4549 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2016 | 2850 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2020 | 2717 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2024 | 3526 | 0.020 |
Why?
|
Anxiety | 1 | 2024 | 4538 | 0.020 |
Why?
|
Chronic Disease | 1 | 2024 | 9266 | 0.020 |
Why?
|
Vomiting | 1 | 2012 | 651 | 0.020 |
Why?
|
Peritoneal Neoplasms | 1 | 2015 | 707 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2014 | 58681 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2005 | 9160 | 0.020 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2015 | 1110 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2015 | 1780 | 0.020 |
Why?
|
Nails, Malformed | 1 | 2007 | 34 | 0.020 |
Why?
|
Neoplasms, Second Primary | 1 | 2015 | 1056 | 0.020 |
Why?
|
Granulation Tissue | 1 | 2007 | 92 | 0.020 |
Why?
|
Palate, Hard | 1 | 2007 | 58 | 0.020 |
Why?
|
Aged | 2 | 2024 | 168217 | 0.020 |
Why?
|
Consensus | 1 | 2016 | 3099 | 0.020 |
Why?
|
Eosinophils | 1 | 2011 | 946 | 0.020 |
Why?
|
Pakistan | 1 | 2007 | 293 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2016 | 6293 | 0.020 |
Why?
|
United States | 2 | 2024 | 72140 | 0.020 |
Why?
|
Anemia | 1 | 2015 | 1504 | 0.020 |
Why?
|
Cranial Fossa, Posterior | 1 | 2006 | 135 | 0.020 |
Why?
|
Immunoglobulin G | 2 | 2011 | 4540 | 0.020 |
Why?
|
Base Sequence | 1 | 2017 | 12436 | 0.020 |
Why?
|
Bone and Bones | 1 | 2016 | 2560 | 0.020 |
Why?
|
Diarrhea | 1 | 2012 | 1317 | 0.020 |
Why?
|
Laminin | 1 | 2007 | 405 | 0.020 |
Why?
|
Hyperpigmentation | 1 | 2007 | 117 | 0.020 |
Why?
|
Disease Management | 1 | 2016 | 2500 | 0.020 |
Why?
|
Sternum | 1 | 2006 | 175 | 0.020 |
Why?
|
Fatigue | 1 | 2012 | 1542 | 0.020 |
Why?
|
Frameshift Mutation | 1 | 2007 | 388 | 0.020 |
Why?
|
Immunoglobulin E | 1 | 2011 | 1484 | 0.020 |
Why?
|
Central Nervous System Vascular Malformations | 1 | 2006 | 140 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2012 | 4839 | 0.010 |
Why?
|
Depression | 1 | 2024 | 8057 | 0.010 |
Why?
|
Germany | 1 | 2006 | 868 | 0.010 |
Why?
|
History, 19th Century | 1 | 2006 | 720 | 0.010 |
Why?
|
Fluorescent Antibody Technique, Direct | 1 | 2003 | 66 | 0.010 |
Why?
|
Antigens, CD34 | 1 | 2005 | 653 | 0.010 |
Why?
|
Weight Gain | 1 | 2012 | 2346 | 0.010 |
Why?
|
Administration, Topical | 1 | 2003 | 697 | 0.010 |
Why?
|
Survival Rate | 1 | 2015 | 12721 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2012 | 3561 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2012 | 10747 | 0.010 |
Why?
|
Sex Factors | 1 | 2013 | 10505 | 0.010 |
Why?
|
Referral and Consultation | 1 | 2012 | 3586 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2015 | 4761 | 0.010 |
Why?
|
Actins | 1 | 2005 | 2049 | 0.010 |
Why?
|
History, 20th Century | 1 | 2006 | 2772 | 0.010 |
Why?
|
Mice | 1 | 2024 | 81107 | 0.010 |
Why?
|
Angiogenesis Inhibitors | 1 | 2005 | 2047 | 0.010 |
Why?
|
Antigens, CD | 1 | 2005 | 3997 | 0.010 |
Why?
|
Animals | 1 | 2024 | 167777 | 0.010 |
Why?
|
Prospective Studies | 1 | 2016 | 54136 | 0.010 |
Why?
|
Algorithms | 1 | 2010 | 13959 | 0.010 |
Why?
|
Heart Defects, Congenital | 1 | 2006 | 4673 | 0.010 |
Why?
|
Prognosis | 1 | 2002 | 29558 | 0.000 |
Why?
|